Romano Brothers & Co’s GSK GSK Stock Holding History

Romano Brothers & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,032	Closed	-$206K	–	308
2024 Q3	$206K	Buy	+5,032	New	+$206K	0.03%	303
2024 Q2	–	Sell	-5,032	Closed	-$216K	–	309
2024 Q1	$216K	Buy	+5,032	New	+$208K	0.03%	295
2023 Q1	–	Sell	-4,872	Closed	-$171K	–	562
2022 Q4	$171K	Buy	+4,872	New	+$162K	0.03%	318

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Romano Brothers & Co's GSK Position: Q4 2024 in Review

Romano Brothers & Co sold out of GSK (GSK) in Q4 2024, closing a stake of 5,032 shares — an estimated $206K sold.

Romano Brothers & Co first reported a position in GSK in Q4 2022 and held it in 3 quarters. The position peaked at $216K in Q1 2024. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

Romano Brothers & Co reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
Romano Brothers & Co sold 5,032 GSK shares in Q4 2024, an estimated $206K.
Romano Brothers & Co first reported a position in GSK in Q4 2022 and held it in 3 quarters.
Romano Brothers & Co's GSK position peaked at $216K in Q1 2024.
848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Romano Brothers & Co's 13F filing for Q4 2024, filed 16 Jan 2025.